The abstract is read at the publisher; the summary is JClub's.
Immune checkpoint inhibitor related pituitary toxicity remains a relatively common complication, with diagnostic uncertainty due to subtle presentations and symptom overlap, and no validated biomarker.
- Why it matters: As immune checkpoint inhibitors improve prognosis in several solid organ malignancies, clinicians need clearer diagnosis, prognostication, and survivorship care for pituitary irAE.
- What they did: This review synthesizes current knowledge on pathogenesis, presentation, biomarkers, and long-term outcomes, highlighting multiple plausible immune pathways that may differ between patients.
- The result: The work supports prioritizing improved phenotyping, biomarker development, and long-term outcomes research to refine diagnosis and endocrine follow-up, including hormone replacement and patient education.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.